Search

Your search keyword '"Alradwan, Ibrahim"' showing total 9 results
Start Over Author "Alradwan, Ibrahim" Search Limiters Full Text
9 results on '"Alradwan, Ibrahim"'

2. Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging.

Author

Alradwan, Ibrahim, AL Fayez, Nojoud, Alomary, Mohammad N., Alshehri, Abdullah A., Aodah, Alhassan H., Almughem, Fahad A., Alsulami, Khulud A., Aldossary, Ahmad M., Alawad, Abdullah O., Tawfik, Yahya M. K., and Tawfik, Essam A.

Subjects
*PERIPHERAL vascular diseases, *TECHNOLOGICAL innovations, *CARDIOVASCULAR diseases risk factors, *CARDIOVASCULAR disease diagnosis, *GENE therapy
Abstract

Cardiovascular diseases (CVDs) are classed as diseases of aging, which are associated with an increased prevalence of atherosclerotic lesion formation caused by such diseases and is considered as one of the leading causes of death globally, representing a severe health crisis affecting the heart and blood vessels. Atherosclerosis is described as a chronic condition that can lead to myocardial infarction, ischemic cardiomyopathy, stroke, and peripheral arterial disease and to date, most pharmacological therapies mainly aim to control risk factors in patients with cardiovascular disease. Advances in transformative therapies and imaging diagnostics agents could shape the clinical applications of such approaches, including nanomedicine, biomaterials, immunotherapy, cell therapy, and gene therapy, which are emerging and likely to significantly impact CVD management in the coming decade. This review summarizes the current anti-atherosclerotic therapies' major milestones, strengths, and limitations. It provides an overview of the recent discoveries and emerging technologies in nanomedicine, cell therapy, and gene and immune therapeutics that can revolutionize CVD clinical practice by steering it toward precision medicine. CVD-related clinical trials and promising pre-clinical strategies that would significantly impact patients with CVD are discussed. Here, we review these recent advances, highlighting key clinical opportunities in the rapidly emerging field of CVD medicine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer

Author

Zetrini, Abdulmottaleb E., primary, Lip, HoYin, additional, Abbasi, Azhar Z., additional, Alradwan, Ibrahim, additional, Ahmed, Taksim, additional, He, Chunsheng, additional, Henderson, Jeffrey T., additional, Rauth, Andrew M., additional, and Wu, Shirley X. Y., additional

Published
2023
Full Text
View/download PDF

5. Abstract 5399: Synergistic combination nanomedicine of doxorubicin and oligo hyaluronic acid inhibits DNA damage repair and overcomes drug resistance in metastatic triple-negative breast cancer

Author

Zhi, Pei, primary, Alradwan, Ibrahim, additional, Zhang, Tian, additional, Lip, HoYin, additional, Zetrini, Abdulmutalib, additional, He, Chunsheng, additional, Henderson, Jeffery, additional, Rauth, Andrew Michael, additional, and Wu, Xiao Yu, additional

Published
2022
Full Text
View/download PDF

6. Cellular responses of hyaluronic acid-coated chitosan nanoparticles† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8tx00041g

Author

Almalik, Abdulaziz, Alradwan, Ibrahim, Majrashi, Majed A., Alsaffar, Bashayer A., Algarni, Abdulmalek T., Alsuabeyl, Mohammed S., Alrabiah, Haitham, Tirelli, Nicola, and Alhasan, Ali H.

Subjects
Chemistry, technology, industry, and agriculture
Abstract

In recent years, nanotechnology has been proven to offer promising biomedical applications for in vivo diagnostics and drug delivery, stressing the importance of thoroughly investigating the biocompatibility of potentially translatable nanoparticles (NPs). Herein, we report the cellular responses of uncoated chitosan NPs (CS NPs) and hyaluronic acid-coated chitosan NPs (HA-CS NPs) when introduced into Chinese hamster ovary cells (CHO-K1) in a dose-dependent manner (2.5, 0.25, 0.025, 0.0025, and 0.00025 mg mL(–1)) at two time points (24 and 48 h). MTS assay, cell proliferation, showed a decrease in the viability of cells when treated with 0.25 and 2.5 mg mL(–1) CS NPs. When exposed to high doses of CS NPs, the lactate dehydrogenase (LDH) enzyme started to leak out of the cells and the cellular levels of mitochondrial potentials were significantly reduced accompanied by a high production of intracellular reactive oxygen species (ROS). Our study provides molecular evidence of the biocompatibility offered by HA-CS NPs, through ROS scavenging capabilities rescuing cells from the oxidative stress, showing no observed cellular stress and thereby revealing the promising effect of anionic hyaluronic acid to significantly reduce the cytotoxicity of CS NPs. Our findings are important to accelerate the translation and utilization of HA-CS NPs in drug delivery, demonstrating the pronounced effect of surface modifications on modulating the biological responses.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results